Galenica AG
SIX:GALE
Galenica AG
Research & Development
Galenica AG
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Galenica AG
SIX:GALE
|
Research & Development
-CHf8.3m
|
CAGR 3-Years
15%
|
CAGR 5-Years
12%
|
CAGR 10-Years
N/A
|
|
Galenica AG
Glance View
In the picturesque landscape of Switzerland, Galenica AG operates as a stalwart in the healthcare sector, seamlessly bridging the gap between pharmaceutical production and retail distribution. Born from a deep-rooted legacy in delivering health solutions, Galenica combines its prowess in logistics with an extensive network of pharmacies spread across the country. The magic of Galenica's operations lies in its unique dual structure. On one hand, it operates a robust logistics arm, supplying a wide array of medicines to healthcare providers, hospitals, and pharmacies. On the other hand, it runs its own retail pharmacy chains, such as Amavita and Sun Store, alongside an e-commerce platform, which make pharmaceutical care more accessible and customer-friendly for the Swiss populace. Galenica's profitability thrives on this diversified business model. By owning the supply chain from logistics to retail, the company maximizes efficiency and reduces costs, positioning itself as a leader in the Swiss pharmaceutical market. Revenue streams flow from wholesale distribution contracts, retail pharmacy sales, and a growing presence in digital health services. Furthermore, in its operations, Galenica integrates a customer-centric philosophy, leveraging data analytics to optimize stock management and personalize customer experiences—effectively enhancing earnings and customer loyalty. Through meticulous execution and strategic expansion, Galenica ensures that it remains an indispensable player in Switzerland's healthcare framework.
See Also
What is Galenica AG's Research & Development?
Research & Development
-8.3m
CHF
Based on the financial report for Dec 31, 2025, Galenica AG's Research & Development amounts to -8.3m CHF.
What is Galenica AG's Research & Development growth rate?
Research & Development CAGR 5Y
12%
Over the last year, the Research & Development growth was 41%. The average annual Research & Development growth rates for Galenica AG have been 15% over the past three years , 12% over the past five years .